Indivior Pharmaceuticals, Inc. (INDV)
| Market Cap | 5.10B |
| Revenue (ttm) | 1.29B |
| Net Income (ttm) | 252.00M |
| Shares Out | 121.92M |
| EPS (ttm) | 1.95 |
| PE Ratio | 21.46 |
| Forward PE | 10.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,608,565 |
| Open | 41.30 |
| Previous Close | 41.29 |
| Day's Range | 41.01 - 42.81 |
| 52-Week Range | 13.47 - 42.81 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 50.71 (+21.23%) |
| Earnings Date | Jul 30, 2026 |
About INDV
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet... [Read more]
Financial Performance
In 2025, Indivior Pharmaceuticals's revenue was $1.24 billion, an increase of 4.29% compared to the previous year's $1.19 billion. Earnings were $210.00 million, an increase of 2900.00%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price target is $50.71, which is an increase of 21.23% from the latest price.
News
Indivior initiated with an Overweight at Barclays
Barclays initiated coverage of Indivior (INDV) with an Overweight rating and $46 price target The firm sees additional upside in the shares in fiscal 2026, driven by Indivior’s turnaround plan…
Indivior reports real-world data for Sublocade in opioid use disorder
Indivior (INDV) Pharmaceuticals announced results from two real-world evidence studies showing that adherence to extended-release buprenorphine, marketed as Sublocade, is associated with lower relapse...
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-rele...
Indivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Gl...
Indivior announces $175M accelerated share repurchase program
Indivior (INDV) announced that it has entered into a $175M accelerated share repurchase agreement with Barclays. The ASR will be executed under Indivior’s existing $400M share repurchase program previ...
Indivior Announces $175 Million Accelerated Share Repurchase
RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”...
Indivior reports Q1 EPS 96c, consensus 66c
Reports Q1 revenue $317M, consensus $272.84M. “We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior (INDV) Action Agenda…
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Q1'26 Total Net Revenue of $317 Million, Up 19% YoY Q1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Re...
Indivior presents real world data on injectable buprenorphine at ASAM Conference
Indivior (INDV) Pharmaceuticals will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine Annual…
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and coll...
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctio...
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026...
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Ind...
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that...
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convert...
Indivior announces proposed convertible senior notes offering
Indivior (INDV) Pharmaceuticals announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 in a private offe...
Indivior Announces Proposed Convertible Senior Notes Offering
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate p...
Indivior announces findings from real-world evidence from study on Sublocade
Indivior (INDV) Pharmaceuticals announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to Sublocade, a mont...
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergenc...
Indivior reports Q4 non-GAAP EPS 82c, consensus 67c
Reports Q4 revenue $358M, consensus $305.62M. “In 2025 we successfully completed Phase I of the Indivior (INDV) Action Agenda – Generate Momentum,” said Joe Ciaffoni, Chief Executive Officer. “We shar...
Indivior board authorizes $400M share repurchase program
“We delivered on our financial commitments in 2025, growing total SUBLOCADE net revenue 13% and adjusted EBITDA 20%, while positioning Indivior (INDV) for acceleration in 2026,” said Ryan Preblick, Ch...
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, and pr...
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, ...
Indivior announces completion of redomiciliation to U.S.
Indivior (INDV) Pharmaceuticals announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, a new Delaware corporation, has become ...
Indivior Announces Completion of Redomiciliation to the United States
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.